Cigna Approves Coverage for Cleerly's AI Cardiovascular Imaging Technology

Major Insurer Joins UnitedHealthcare in Covering Cleerly's AI-QCT/AI-CPA Technology, Expanding Access to 61 Million Americans

DENVER--(BUSINESS WIRE)--Cleerly, a leader in AI-based cardiovascular imaging, today announced that Cigna will begin covering Cleerly LABS Advanced Plaque Analysis effective October 1, 2025. The coverage decision makes Cigna the latest major insurer to recognize the clinical and economic value of Artificial Intelligence Enabled CT Based Quantitative Coronary Tomography (AI-QCT)/Coronary Plaque Analysis (AI-CPA) technology for cardiovascular care.

With more than 16 million covered lives, Cigna joins UnitedHealthcare and EviCore in providing Cleerly's advanced imaging technology. Combined with Medicare's 2024 coverage decision and the technology's upcoming CPT I code going into effect January 2026, major payors now cover AI-QCT/AI-CPA for over 61 million Americans, representing unprecedented industry adoption.

Coverage Details

Beginning October 1, 2025, all Cigna health plans will cover AI-QCT/AI-CPA imaging for patients who meet established clinical criteria:

• The patient has acute or stable chest pain with no known CAD and is eligible for CCTA AND
• CCTA classifies patient as:
  • Intermediate risk OR
  • CAD-RADS 1, CAD-RADS 2 or CAD-RADS 3, category on CCTA, AND
• Cardiac evaluation is negative or inconclusive for acute coronary syndrome (ACS)

"We're witnessing a fundamental transformation in cardiovascular care," said James K. Min, MD, founder and CEO of Cleerly. "Major insurers now recognize that advanced plaque analysis through our AI-QCT technology enhances clinical insights and supports clinicians in making more informed care decisions. This represents a pivotal moment for precision medicine in cardiology."

The rapid payor adoption reflects mounting clinical evidence that AI-QCT enhances diagnostic accuracy enabling more informed clinical decisions and reducing healthcare expenditures. This advancement is particularly significant given that cardiovascular disease remains the leading cause of death in the United States, affecting millions of Americans and driving substantial healthcare costs.

Visit www.cleerlyhealth.com to learn more.

About Cleerly

Cleerly is the company on a mission to eliminate heart attacks by creating a new standard of care for heart disease. Through its FDA-cleared solutions driven by artificial intelligence, Cleerly supports comprehensive phenotyping of coronary artery disease, as determined from advanced noninvasive CT imaging. Cleerly’s approach is grounded in science, based on millions of images from over 40,000 patients. Led by a world-class clinical and technical team, Cleerly enhances health literacy for each and every stakeholder in the coronary care pathway. For more information, please visit: cleerlyhealth.com.